{
    "response": "**Overall Treatment Decision:** Yes\u2014initiate\n\n**Specific Treatment Recommendations:**\n\n*   **Treatment:** Intravenous methylprednisolone 1 g daily for 3\u20135 days\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Acute unilateral optic neuritis within treatment window Speeds visual recovery Standard first-line therapy for inflammatory optic neuritis\n\n*   **Treatment:** Oral prednisolone taper (e.g., 60 mg reducing over 11\u201314 days) after IV course\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Reduces early relapse risk after IV steroids Bridges steroid withdrawal following pulse therapy\n\n*   **Treatment:** Proton pump inhibitor and glucose/BP monitoring during steroids\n*   **Initiation Timing:** Start Now\n*   **Clinical Reasoning for Timing:** Mitigate gastrointestinal and metabolic adverse effects of high-dose steroids\n\n*   **Treatment:** Plasma exchange (5\u20137 exchanges)\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Reserve for steroid-refractory or severe vision loss Initiate if no improvement within 3\u20135 days post-steroids or AQP4-positive severe attack\n\n*   **Treatment:** Multiple sclerosis disease-modifying therapy\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Start only if MRI/CSF support MS diagnosis or high-risk clinically isolated syndrome Choice depends on lesion burden and patient factors\n\n*   **Treatment:** Rituximab or other NMOSD-directed immunotherapy\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Indicated if AQP4-IgG positive or high clinical suspicion Requires serologic confirmation and specialist planning\n\n*   **Treatment:** Targeted antimicrobial therapy (e.g., for syphilis, TB, Lyme) if confirmed\n*   **Initiation Timing:** Delay\n*   **Clinical Reasoning for Timing:** Treat only if infectious cause identified Avoid unnecessary antibiotics without evidence\n\n\ntreatments = [{\"treatment\": \"Intravenous methylprednisolone 1 g daily for 3\\u20135 days\", \"timing\": \"Start Now\", \"reasons\": [\"Acute unilateral optic neuritis within treatment window\", \"Speeds visual recovery\", \"Standard first-line therapy for inflammatory optic neuritis\"]}, {\"treatment\": \"Oral prednisolone taper (e.g., 60 mg reducing over 11\\u201314 days) after IV course\", \"timing\": \"Start Now\", \"reasons\": [\"Reduces early relapse risk after IV steroids\", \"Bridges steroid withdrawal following pulse therapy\"]}, {\"treatment\": \"Proton pump inhibitor and glucose/BP monitoring during steroids\", \"timing\": \"Start Now\", \"reasons\": [\"Mitigate gastrointestinal and metabolic adverse effects of high-dose steroids\"]}, {\"treatment\": \"Plasma exchange (5\\u20137 exchanges)\", \"timing\": \"Delay\", \"reasons\": [\"Reserve for steroid-refractory or severe vision loss\", \"Initiate if no improvement within 3\\u20135 days post-steroids or AQP4-positive severe attack\"]}, {\"treatment\": \"Multiple sclerosis disease-modifying therapy\", \"timing\": \"Delay\", \"reasons\": [\"Start only if MRI/CSF support MS diagnosis or high-risk clinically isolated syndrome\", \"Choice depends on lesion burden and patient factors\"]}, {\"treatment\": \"Rituximab or other NMOSD-directed immunotherapy\", \"timing\": \"Delay\", \"reasons\": [\"Indicated if AQP4-IgG positive or high clinical suspicion\", \"Requires serologic confirmation and specialist planning\"]}, {\"treatment\": \"Targeted antimicrobial therapy (e.g., for syphilis, TB, Lyme) if confirmed\", \"timing\": \"Delay\", \"reasons\": [\"Treat only if infectious cause identified\", \"Avoid unnecessary antibiotics without evidence\"]}]"
}